P-0128 HIV-Associated Lymphoma of the Gastrointestinal Tract in the Combination Antiretroviral Therapy Era

Abstract

ABSTRACT Introduction HIV-associated non-Hodgkin's lymphoma (NHL) remains the most common HIV-associated malignancy despite the advent of combination antiretroviral therapy (cART). The gastrointestinal (GI) tract is one of the most common extranodal sites. GI NHL can be divided into primary GI lymphoma and secondary involvement from diffuse nodal disease. The median survival time of HIV-associated lymphoma with GI tract involvement in the pre-cART era was 4–10 months. The aim of this study is to investigate its characteristics and survival outcomes in the cART era. Methods We retrospectively analyzed the medical records of patients (including 2023 HIV-infected patients) diagnosed with GI lymphoma between April 2000 and December 2011 at Osaka National Hospital. Results Seventy-four patients had been diagnosed with GI lymphoma (primary or systemic lymphoma with GI involvement) with (14 patients) or without (60 patients) HIV infection. Of the 2023 HIV-infected patients, 14 had been diagnosed with GI lymphoma. One of these patients had been diagnosed with primary gastric diffuse large B-cell lymphoma (DLBCL) on autopsy. Of the 13 patients, 5 had primary GI lymphoma and 8 had systemic lymphoma with GI tract involvement. The median age at presentation was 44 years (range, 32–72 years), median CD4 lymphocyte count was 101/mm3 (range, 4–560/mm3), and median HIV RNA viral load was 52000 copies (range, Conclusion In HIV-associated lymphoma with GI tract involvement, survival is better in the cART era than the pre-cART era. The overall survival of HIV-infected patients with GI aggressive B-cell lymphomas was similar to that of HIV-negative patients with such lymphomas.